Despite variability in cohort composition, transplant protocols, and outcome reporting, our systematic review highlights the heterogeneous clinical course of GATA2-MDS/AML and reinforces HSCT as the cornerstone of treatment. This evidence concerns the gene GATA2 and myelodysplastic syndrome.